These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25407815)

  • 21. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
    Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT;
    Int J Gynecol Cancer; 2014 Jun; 24(5):857-64. PubMed ID: 24844219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.
    Liu JF; Palakurthi S; Zeng Q; Zhou S; Ivanova E; Huang W; Zervantonakis IK; Selfors LM; Shen Y; Pritchard CC; Zheng M; Adleff V; Papp E; Piao H; Novak M; Fotheringham S; Wulf GM; English J; Kirschmeier PT; Velculescu VE; Paweletz C; Mills GB; Livingston DM; Brugge JS; Matulonis UA; Drapkin R
    Clin Cancer Res; 2017 Mar; 23(5):1263-1273. PubMed ID: 27573169
    [No Abstract]   [Full Text] [Related]  

  • 23. Neoadjuvant chemotherapy fails to improve survival in advanced ovarian cancer: but is it the real culprit?
    Di Giorgio A; Sammartino P; Biacchi D
    Int J Gynecol Cancer; 2011 May; 21(4):596. PubMed ID: 21543925
    [No Abstract]   [Full Text] [Related]  

  • 24. [Epithelial ovarian cancer].
    Hilpert F; Krause G; Venhoff L; Kühnle E; Schem C; Maass N
    Ther Umsch; 2007 Jul; 64(7):375-80. PubMed ID: 17948754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of evidence-based medicine on the decision of chemotherapy for epithelial ovarian cancer].
    Li GT
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):582-6. PubMed ID: 23141177
    [No Abstract]   [Full Text] [Related]  

  • 26. The efficacy of trabectedin in treating ovarian cancer.
    Teplinsky E; Herzog TJ
    Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
    Hou MM; Wang Z; Janku F; Piha-Paul S; Naing A; Hong D; Westin S; Coleman RL; Sood AK; Tsimberidou AM; Subbiah V; Wheler J; Zinner R; Lu K; Meric-Bernstam F; Fu S
    Oncotarget; 2016 Jun; 7(23):35132-43. PubMed ID: 27147567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model.
    Lee Y; Kollara A; May T; Brown TJ
    J Ovarian Res; 2018 Jul; 11(1):56. PubMed ID: 29973223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral cyclophosphamide in recurrent ovarian cancer.
    Handolias D; Quinn M; Foo S; Mileshkin L; Grant P; Dutu G; Rischin D
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e154-60. PubMed ID: 23718870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.
    Plamadeala V; Kelley JL; Chan JK; Krivak TC; Gabrin MJ; Brower SL; Powell MA; Rutherford TJ; Coleman RL
    Gynecol Oncol; 2015 Jan; 136(1):94-8. PubMed ID: 25462203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.
    Hu CF; Ou YC; Fu HC; Chang Chien CC; Tsai CC; Wu CH; Lin H
    Taiwan J Obstet Gynecol; 2015 Feb; 54(1):43-7. PubMed ID: 25675918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?
    Tomao F; D'Incalci M; Biagioli E; Peccatori FA; Colombo N
    Cancer; 2017 Sep; 123(18):3450-3459. PubMed ID: 28678350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors in epithelial ovarian cancer: A population-based study.
    Chang LC; Huang CF; Lai MS; Shen LJ; Wu FL; Cheng WF
    PLoS One; 2018; 13(3):e0194993. PubMed ID: 29579127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance.
    Chuang YT; Chang CL
    Taiwan J Obstet Gynecol; 2012 Sep; 51(3):336-41. PubMed ID: 23040913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
    Oza A; Kaye S; Van Tornout J; Sessa C; Gore M; Naumann RW; Hirte H; Colombo N; Chen J; Gorla S; Poondru S; Singh M; Steinberg J; Yuen G; Banerjee S
    Gynecol Oncol; 2018 May; 149(2):275-282. PubMed ID: 29454514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of primary and recurrent ovarian cancer].
    Rosendahl M; Mosgaard BJ; Steffensen KD
    Ugeskr Laeger; 2018 Jan; 180(4):. PubMed ID: 29393032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent epithelial ovarian cancer: an update on treatment.
    Foley OW; Rauh-Hain JA; del Carmen MG
    Oncology (Williston Park); 2013 Apr; 27(4):288-94, 298. PubMed ID: 23781692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.